{
    "symbol": "SNDX",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-09 20:13:09",
    "content": " We're also pleased to announce that we have enrolled our first patients in the BEAT-AML and AUGMENT-102 trials, which represent important expansion opportunities for the franchise in combination with other approved agents and begin to move us into newly diagnosed patients. As we continue to develop Revumenib for use beyond treatment of relapsed/refractory patients, and into the first-line treatment setting we see the opportunity to treat up to 12,500 patients identified each year with these two forms of mutant acute leukemia. As we previously mentioned, it was our intention, we plan to initiate a robust Phase 2 trial in IPF in the fourth quarter of this year the first expansion outside of establishing cGVHD as a beachhead into other fibrotic diseases, where we believe axatilimab could have a significant impact. Your line is now open. Your line is now open. Your line is now open. Your line is now open. I mean it's -- I wouldn't necessarily think about novel, we want to just sort of see is this -- it does the preclinical data or the clinic -- obviously is there are additional opportunities if it does work and it\u2019d be b-catenin pathway beyond colorectal cancer. Your line is now open. Your line is now open."
}